eye disease

Beacon shines a light on positive early data from eye disease ph. 2

The company's gene therapy made for improvements in visual function for patients with X-linked retinitis pigmentosa at six months in its phase 2 study.

Zoey Becker May 7, 2025 7:15am

Large layoffs of employees Wooden figures of people going to the exit

Opthea lays off 65% of staff after back-to-back phase 3 flops

Apr 10, 2025 7:52am

Tenvie takes off with $200M, assets and exec from Denali

Jan 8, 2025 8:00am

mRNA therapy reduced post-surgery eye scarring in rabbits

Nov 27, 2024 2:00pm

eye doctor opthalmology phoropter glasses eye disease vision

AlloVir finds new identity via eye disease biotech merger

Nov 8, 2024 9:05am

Ocuphire to transform into gene therapy biotech via Opus buyout

Oct 23, 2024 5:31am